Inventor
ENGELS BORIS
US17 patents
⚠️ This page may combine multiple inventors who share the name “ENGELS BORIS”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
NOVARTIS AG
16 patentsUS10525083B2Jan 7, 2020
Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
NOVARTIS AG15 citations93
US10287354B2May 14, 2019
Regulatable chimeric antigen receptor
NOVARTIS AG29 citations92
US10640569B2May 5, 2020
Human mesothelin chimeric antigen receptors and uses thereof
NOVARTIS AG15 citations83
US11026976B2Jun 8, 2021
Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
NOVARTIS AG6 citations82
US10577417B2Mar 3, 2020
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
NOVARTIS AG10 citations82
US11413340B2Aug 16, 2022
Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
NOVARTIS AG2 citations72
US11872249B2Jan 16, 2024
Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domain
NOVARTIS AG2 citations71
US11975026B2May 7, 2024
CD19 and CD22 chimeric antigen receptors and uses thereof
NOVARTIS AG3 citations70
US12186278B2Jan 7, 2025
Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
NOVARTIS AG0 citations62
US12594321B2Apr 7, 2026
Bispecific chimeric antigen receptor that binds CD19 and CD20, encoding nucleic acid molecules thereof and methods of use thereof to treat cancer
NOVARTIS AG0 citations61
USRE49847EFeb 27, 2024
Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
NOVARTIS AG0 citations61
US11578130B2Feb 14, 2023
Regulatable chimeric antigen receptor
NOVARTIS AG1 citations61
US11999794B2Jun 4, 2024
Human mesothelin chimeric antigen receptors and uses thereof
NOVARTIS AG0 citations60
US11981731B2May 14, 2024
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
NOVARTIS AG0 citations60
US12344651B2Jul 1, 2025
CD19 and CD22 chimeric antigen receptors and uses thereof
NOVARTIS AG1 citations59
US12383601B2Aug 12, 2025
Chimeric antigen receptors and uses thereof
NOVARTIS AG1 citations57